homepage menafrinet
AN INTERNATIONAL NETWORK OF PARTNERS IN SUPPORT OF QUALITY MENINGITIS SURVEILLANCE AND DATA
handsworkinginlab
Working collaboratively to decrease the burden of bacterial meningitis in Africa

MenAfriNet is an international consortium of partners working to establish a regional surveillance network to collect and analyze high quality case-based meningitis surveillance data from representative sites across the meningitis belt of Africa. The consortium works to evaluate current vaccine programs, monitor disease trends, and inform future vaccine decisions in the sub-Saharan African meningitis belt.

Deadly, Expensive, Preventable

beltmap

Serogroup A meningococcal meningitis threatens the lives of 450 million people across 26 countries in Africa's meningitis belt.

Historically, 8 in 10 cases of meningitis in this region are caused by serogroup A meningococcus. Treatment is costly for both families and nations, and contributes to the cycle of poverty. Each case of meningitis in a family results in a sudden cost of about 3 or 4 months of the family's income. The permanent disabilities caused by meningitis leave survivors less able to care for themselves and less likely to earn income.

MenAfriNet is a network of international partners supporting quality meningitis data for Africa to evaluate the impact of a novel meningococcal A conjugate vaccine, MenAfriVac®.

Icon of group of people
The vaccine is targeted to protect 450 million people at risk.
Icon of person, jeep, and row boat
MenAfriVac® is the first vaccine made specifically for use in Africa.
Icon of scales
MenAfriVac® costs only $0.40 per dose, far less than the $90 needed to treat just one person.